The latest update is out from Everest Medicines Ltd. ( (HK:1952) ).
Everest Medicines Ltd. announced its audited annual results for the year ending December 31, 2024, which have been reviewed by its audit committee and auditors, Ernst & Young. The results are available in both Chinese and English on the company’s and the Hong Kong Stock Exchange’s websites, with printed versions to be distributed to shareholders by April 2025. This announcement reflects the company’s compliance with the listing requirements and provides stakeholders with insights into its financial health and operational performance.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of transformative pharmaceutical products. The company is listed on the Hong Kong Stock Exchange and is dedicated to addressing critical unmet medical needs in Asia and globally.
YTD Price Performance: 34.61%
Average Trading Volume: 5,463,469
Technical Sentiment Signal: Sell
Current Market Cap: HK$20.46B
For a thorough assessment of 1952 stock, go to TipRanks’ Stock Analysis page.